Skip to main content
. 2022 Mar 28;14(4):723. doi: 10.3390/pharmaceutics14040723

Table 4.

Intraocular pressure outcomes.

N (%)
Parameters after FAc
Δ IOP < 6 mmHg (low responder)
Δ IOP 6–15 mmHg (intermediate responder)
Δ IOP > 15 mmHg (high responder)

43 (69.4%)
17 (27.4%)
2 (3.2%)
IOP > 21 mmHg
IOP > 25 mmHg
IOP > 30 mmHg
IOP > 25 mmHg and/or gain > 10 mmHg (OHT)
IOP > 30 mmHg and/or gain > 15 mmHg
6 (9.7%)
4 (6.5%)
1 (1.6%)
7 (11.3%)
2 (3.2%)
IOP procedures after FAc:
All
Introduction of monotherapy
Introduction of dual therapy
Switch monotherapy to dual therapy
Switch dual therapy to quadruple therapy
SLT only
Total of SLT
IOP-lowering surgery following topical therapy

11 (17.7%)
2 (3.2%)
2 (3.2%)
4 (6.5%)
1 (1.6%)
2 (3.2%)
4 (6.5%)
1 (1.6%)

BCVA: best corrected visual acuity; CMT: central macular thickness; DM: diabetes mellitus; DME: diabetic macular edema; DRIL: disorganization of retinal inner layers; ETDRS: early treatment diabetic retinopathy study; EZ/IZ: ellipsoid/interdigitation zone; HRF: hyperreflective foci; IRF: intraretinal fluid; PRP: panretinal photocoagulation SD: standard deviation; SRF: subretinal fluid.